The entryway at #ASH19 Each ASH annual meeting has its own ‘flavor’ and emphasis regarding myeloma. I’ve been to several and remember the excitement of ASH2015 after our unprecedented elotuzumab, daratumumab, Ninlaro, “November to Remember.” Last year the emphasis was on early immunotherapy with BiTEs, CAR-T, and ADCs (antibody drug conjugates). This year ASH2019 was […]
I attended a session on palliative care, Billed Palliative Care and End of Life Care in Patients with Hematologic Malignancies presented by V. Rao from Warren Alpert Medical School of Brown University. I thought it was interesting that palliative care was not defined in the talk. I suppose the assumption was the audience knew the […]
In the United States, twelve novel drugs have been approved for the treatment of myeloma over the last 16 years driven by results of clinical trials similar to those that are being presented here at #ASH19. According to clinicaltrials.gov website, as of December 2019, there were more than 500 clinical trials in progress for myeloma. […]
